New classes of biological drugs that block the production or action of Th2-related cytokines (IL-4, IL-5, IL-13) are making important progress toward new therapeutic paradigms in CRSwNP and its endotypes [37]. This evidence concerns the gene IL4 and chronic rhinosinusitis with nasal polyps.